Biocartis NV

Biocartis NV is a molecular diagnostics company specializing in fully automated, real-time PCR-based testing systems for personalized medicine. The company's flagship product, Idylla™, is a revolutionary automated molecular testing platform designed to deliver actionable biomarker results in approximately 3 hours. Idylla operates as a decentralized laboratory solution suitable for diverse healthcare settings, enabling pathologists and oncologists to obtain molecular diagnostic results rapidly for clinical decision-making. The system is particularly focused on oncology applications, where timely molecular biomarker analysis—including companion diagnostics—is critical for treatment selection and patient outcomes. Biocartis positions Idylla as addressing the challenge of making molecular testing easy, fast, and accessible to any laboratory, regardless of size or prior molecular expertise. The company supports oncology research into emerging biomarkers and maintains active partnership programs with pharmaceutical and in vitro diagnostics companies to expand the clinical utility of its platform. Biocartis' vision centers on enabling universal access to molecular testing globally, reducing barriers to personalized medicine adoption. The platform leverages automation and standardization to minimize hands-on time and technical variability, making molecular diagnostics suitable for point-of-care and decentralized laboratory environments.